Skip to main content
SpringerLink
Log in

Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Genetically determined polymorphisms of N-acetylation and oxidative capacity have been studied using dapsone and metoprolol in 51 Japanese patients with spontaneous bladder cancer and 203 healthy control subjects.

The results for N-acetylation pharmacogenetics were against the initial expectation that there would be a preponderance of slow acetylators in the cancer group, as 3 such patients (5.9%) were found as compared to 13 (6.4%) in the healthy group. There was no poor metabolizer (PM) of metoprolol in the cancer group, whereas in the healthy group one (0.5%) was a PM. There were no significant differences between the groups in the frequency of slow acetylator and poor oxidiser phenotypes, or in the frequency distribution profiles of acetylation (monoacetyldapsone/dapsone) and oxidative metabolic ratio (log metoprolol/α-hydroxymetoprolol).

The results indicate that neither N-acetylation nor the debrisoquine/sparteine-type oxidative phenotype and/or capacity represent a genetic predisposition to spontaneous bladder carcinogenesis in Japanese patients. In the normal Japanese population there is a great predominance of rapid acetylators and extensive oxidisers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Weber WW (1987) The acetylator genes and drug response. Oxford University Press, New York

    Google Scholar 

  2. Evans DAP (1984) Survey of the human acetylator polymorphism in spontaneous disorders. J Med Genet 21: 243–253

    Google Scholar 

  3. Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Hall DB, Higgins E, Kahn MA (1982) The role of N-acetyltransferase phenotype in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer. Lancet 2: 842–846

    Google Scholar 

  4. Cartwright RA (1984) Epidemiological studies on N-acetylation and C-center oxidation in neoplasia. In: Omens GS, Gelboin HV (eds) Genetic variability in responses to chemical exposure. Banbury Reports, Cold Spring Harbor Laboratory, vol 16, pp 359–368

  5. Ladero JM, Kwok CK, Jara C, Fernandez L, Silmi AM, Tapia D, Uson AC (1985) Hepatic acetylator phenotype in bladder cancer patients. Ann Clin Res 17: 96–99

    Google Scholar 

  6. Hanssen HP, Agarwal DP, Goedde HW, Bucher H, Huland H, Brachmann W, Ovenbeck R (1985) Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Study in a North German population. Eur Urol 11: 263–266

    Google Scholar 

  7. Lower GM, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT (1979) N-Acetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 29: 71–79

    Google Scholar 

  8. Wolf H, Lower GM, Bryan GT (1980) Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines. Scand J Urol Nephrol 14: 161–165

    Google Scholar 

  9. Woodhouse KW, Adams PC, Clothier A, Mucklow JC, Rawlins MD (1982) N-Acetylation phenotype in bladder cancer. Human Toxicol 1: 443–445

    Google Scholar 

  10. Mommsen S, Sell A, Barfod N (1982) N-Acetyltransferase phenotypes of bladder cancer patients in a low-risk population. Lancet 2: 1228

    Google Scholar 

  11. Miller ME, Cosgriff JM (1983) Acetylator phenotype in human bladder cancer. J Urol 130: 65–66

    Google Scholar 

  12. Evans DAP, Eze LC, Whibley EJ (1983) The association of the slow acetylator phenotype with bladder cancer. J Med Genet 20: 330–333

    Google Scholar 

  13. Mommsen S, Barfod NM, Aagaard J (1985) N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population. Carcinogenesis 6: 199–201

    Google Scholar 

  14. Mommsen S, Aagaard J (1986) Susceptibility in urinary bladder cancer: Acetyltransferase phenotypes and related risk factors. Cancer Lett 32: 199–205

    Google Scholar 

  15. Kaisary A, Smith P, Jacqz E, McAllister CB, Wilkinson GR, Ray WA, Branch RA (1987) Genetic predisposition to bladder cancer: Ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 47: 5488–5493

    Google Scholar 

  16. Eichelbaum M (1982) Defective oxidation of drugs: Pharmacokinetic and therapeutic implications. Clin Pharmacokinet 7: 1–22

    Google Scholar 

  17. Jacqz E, Hall SD, Branch RA (1986) Genetically determined polymorphisms in drug oxidation. Hepatology 6: 1020–1032

    Google Scholar 

  18. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 1: 584–586

    Google Scholar 

  19. Eichelbaum M, Spannbruker N, Steincke B, Dengler HJ (1979) Defective oxidation of sparteine in man. A new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187

    Google Scholar 

  20. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105

    Google Scholar 

  21. Kadlubar FF (1987) Metabolism and DNA binding of carcinogenic aromatic amines. ISI Atlas Sci 1: 129–132

    Google Scholar 

  22. Cartwright RA, Philip PA, Rogers HJ, Glashan RW (1984) Genetically determined debrisoquine capacity in bladder cancer. Carcinogenesis 5: 1191–1192

    Google Scholar 

  23. Sunahara S, Urano M, Ogawa M (1961) Genetical and geographic studies on isoniazid inactivation. Science 134: 1530–1531

    Google Scholar 

  24. Horai Y, Ishizaki T (1988) N-Acetylation polymorphism of dapsone in a Japanese population. Br J Clin Pharmacol 25: 487–494

    Google Scholar 

  25. UICC. TNM Classification of malignant tumours. Fourth, fully revised edition (1987) Hermanek P, Sobin LH (eds) Springer-Verlag, Berlin Heidelberg New York

    Google Scholar 

  26. Horai Y, Ishizaki T, Kusaka M, Tsujimoto G, Hashimoto K (1988) Simultaneous determination of metoprolol and α-hydroxymetoprolol in human plasma and urine by liquid chromatography with a preliminary observation on metoprolol oxidation in Japanese subjects. Ther Drug Monit 10: 428–433

    Google Scholar 

  27. Horai Y, Zhou H-H, Zhang L-M, Ishizaki T (1988) N-Acetylation phenotyping with dapsone in a mainland Chinese population. Br J Clin Pharmacol 25: 81–87

    Google Scholar 

  28. Horai Y, Ishizaki T (1985) Rapid and sensitive liquid chromatographic method for the determination of dapsone and monoacetyldapsone in plasma and urine. J Chromatogr 345: 447–452

    Google Scholar 

  29. Reidenberg MM, Drayer DE, Levy M, Warner H (1975) Polymorphic acetylation of procainamide in man. Clin Pharmacol Ther 17: 722–730

    Google Scholar 

  30. Carr K, Oates JA, Nies AS, Woosley RL (1978) Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype. Br J Clin Pharmacol 6: 421–427

    Google Scholar 

  31. McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF (1985) Metoprolol metabolism and debrisoquine oxidation polymorphism — population and family studies. Br J Clin Pharmacol 20: 555–566

    Google Scholar 

  32. Case RAM, Hosker ME, McDonald DB, Pearson JT (1954) Tumors of the urinary bladder in workman engaged in the manufacture and use of certain dyestuff intermediates in the British Chemical Industry. Role of aniline, benzidine, alpha-naphthylamine, and beta-naphthylamine. Br J Ind Med 11: 75–104

    Google Scholar 

  33. Radomski JL, Brill E (1970) Bladder cancer induction by aromatic amines: Role of N-hydroxy metabolites. Science 167: 992–993

    Google Scholar 

  34. Lower GM (1982) Concepts in causality: Chemically induced human urinary bladder cancer. Cancer 49: 1056–1066

    Google Scholar 

  35. Lunde PKM, Frislid K, Hasteen V (1977) Disease and acetylation polymorphism. Clin Pharmacokinet 2: 182–197

    Google Scholar 

  36. Ishizaki T, Horai Y, Koya G, Matsuyama K, Iguchi S (1981) Acetylator phenotype and metabolic disposition of isoniazid in Japanese patients with systemic lupus erythematosus. Arthritis Rheum 24: 1245–1254

    Google Scholar 

  37. Horai Y, Ishizaki T, Sasaki T, Koya G, Matsuyama K, Iguchi S (1982) Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects. Br J Clin Pharmacol 13: 361–374

    Google Scholar 

  38. Philip PA, Gayed SL, Rogers HJ, Crome P (1987) Influence of age, sex and body weight on the dapsone acetylation phenotype. Br J Clin Pharmacol 23: 709–713

    Google Scholar 

  39. Eichelbaum M, Reetz K-P, Schmidt EK, Zekorn C (1986) The genetic polymorphism of sparteine metabolism. Xenobiotica 16: 465–481

    Google Scholar 

  40. Ohkawa T, Fujinaga T, Doi J, Ebisuno S, Takamatsu M, Nakamura J, Kido R (1982) Clinical study on occupational uroepithelial cancer in Wakayama City. J Urol 128: 520–523

    Google Scholar 

  41. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402–408

    Google Scholar 

  42. Ishizaki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler HJ (1987) Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol 23: 482–485

    Google Scholar 

  43. Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR (1984) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312: 169–170

    Google Scholar 

  44. Idle JR, Mahgoub A, Sloan TP, Smith RL, Mbanefo CO, Bababunmi EA (1981) Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer. Cancer Lett 11: 331–338

    Google Scholar 

  45. Cole P, Monson RR, Haning H, Friedell GH (1971) Smoking and cancer of the lower urinary tract. N Engl J Med 284: 129–134

    Google Scholar 

  46. Wynder EL, Goldsmith R (1977) The epidemiology of bladder cancer. A second look. Cancer 40: 1246–1268

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacology, Clinical Research Institute, Tokyo, Japan

    Y. Horai & T. Ishizaki

  2. Department of Urology, National Medical Center, Tokyo, Japan

    K. Fujita

Authors
  1. Y. Horai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Fujita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Ishizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horai, Y., Fujita, K. & Ishizaki, T. Genetically determined N-acetylation and oxidation capacities in Japanese patients with non-occupational urinary bladder cancer. Eur J Clin Pharmacol 37, 581–587 (1989). https://doi.org/10.1007/BF00562549

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00562549

Key words

Search

Navigation